Paper Details

  1. Home
  2. Paper Details

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.

Author: AddepalliMurali K, AliCherie F, ChangThomas K, CharychDeborah H, DobersteinStephen K, HochUte, HuangJicai, JiChunmei, KanhereRupesh S, KantakSeema S, KirkPeter B, KirkseyYolanda M, KonakovaMarina, LangowskiJohn L, LeeSteve R, LiuXiaofeng, PenaRhoneil L, ShengDawei, SimsPaul W, SweeneyTheresa D, VanderVeenLaurie A, WangYujun

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

NKTR-214, a prodrug of conjugated IL2, may reduce the side effects of aldesleukin, an immunotherapy for metastatic melanoma and renal cancer, while retaining its effectiveness.
Paper Details　
Original Abstract of the Article :
Aldesleukin, recombinant human IL2, is an effective immunotherapy for metastatic melanoma and renal cancer, with durable responses in approximately 10% of patients; however, severe side effects limit maximal dosing and thus the number of patients able to receive treatment and potential cure. NKTR-21...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1158/1078-0432.CCR-15-1631

データ提供：米国国立医学図書館（NLM）

A New Approach to IL2 Therapy: NKTR-214

The field of immunotherapy for cancer is constantly evolving, and this study investigates a new approach to IL2 therapy with the drug NKTR-214. This research delves into the use of a prodrug of conjugated IL2, designed to enhance tumor exposure and efficacy while minimizing adverse effects. The authors explore how NKTR-214, with its unique design, can overcome the limitations of traditional IL2 therapy, specifically the severe side effects. They discovered that NKTR-214 demonstrates significant efficacy in mouse tumor models, providing a glimmer of hope for better treatment options for patients with metastatic melanoma and renal cancer.

Promising Results for Cancer Treatment

This research highlights the potential of NKTR-214 to revolutionize IL2 therapy. The study reveals that NKTR-214, with its modified structure, exhibits a remarkable ability to target tumors more effectively while reducing the severity of side effects. The study's findings in mouse models offer a compelling case for further investigation into the therapeutic potential of NKTR-214 in human patients. If successful, this could potentially lead to a new era in IL2-based immunotherapy, offering a more tolerable and effective treatment option for a wider range of cancer patients.

Hope for a More Tolerable Treatment

The research explores a promising avenue for improving IL2 therapy. By addressing the challenges associated with traditional IL2 treatment, the study suggests a pathway towards a more tolerable and effective treatment option for patients with metastatic melanoma and renal cancer. This could translate into enhanced quality of life and potentially better outcomes for these patients.

Dr.Camel's Conclusion

This study sheds light on the promising future of immunotherapy, particularly in the realm of IL2 therapy. The innovative design of NKTR-214 provides a potential solution to the challenges of traditional IL2 treatments, offering hope for a more effective and tolerable therapeutic approach. This research serves as a crucial stepping stone in the ongoing quest for better cancer treatments, with the potential to impact the lives of many patients. It's like finding a new oasis in the vast desert of cancer treatment research!
Date :
  1. Date Completed 2016-10-25
  2. Date Revised 2021-11-30
Further Info :

Pubmed ID

26832745

DOI: Digital Object Identifier

10.1158/1078-0432.CCR-15-1631

Related Literature

Article Analysis
・Side Effects of aldesleukin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.